Curative Biotechnology (CUBT) S-1 15 Apr 22 IPO registration Financial data

Cover

Cover	12 Months Ended
	Dec. 31, 2021
Cover [Abstract]
Document Type	S-1
Amendment Flag	false
Entity Registrant Name	Curative Biotechnology Inc
Entity Central Index Key	0001400271
Entity Primary SIC Number	2836
Entity Tax Identification Number	26-1412177
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	1825 NW Corporate Blvd
Entity Address, Address Line Two	Suite 110
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33431
City Area Code	(561)
Local Phone Number	907-8990
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Document Creation Date	Apr. 15, 2022

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
CURRENT ASSETS
Cash	$ 670,263	$ 160,607
Subscription receivable	25,000
Prepaid expenses	58,642	1,900,859
Funds receivable on notes payable		70,000
Total current assets	753,905	2,131,466
FIXED ASSETS
Property and equipment	6,834	81,515
Accumulated depreciation	(114)	(79,177)
Total fixed assets	6,720	2,338
OTHER ASSETS
Deferred offering costs	92,975
Intangible assets, net	1,558,550	140,300
Total other assets	1,651,525	140,300
Total Assets	2,412,150	2,274,104
CURRENT LIABILITIES
Accounts payable and accrued liabilities	726,904	97,830
Convertible note payable		128,700
Liability to issue common shares	3,431	7,400
Short term note payable - related parties, net of discounts		25,415
Third party short term loans, net of discounts		405,646
Total current liabilities	730,335	664,991
Total Liabilities	730,335	664,991
Commitments and Contingencies
DEFICIENCY IN STOCKHOLDERS’ EQUITY
Preferred stock, $0.0001 par value, authorized 200,000,000 shares, Series B 81,000 and 293,000 shares issued and outstanding	8	29
Common stock, $0.0001 par value, authorized 1,100,000,000 shares; 570,651,636 and 333,000,327 shares issued and outstanding	57,065	33,300
Additional paid-in capital	10,498,221	3,544,658
Accumulated deficit	(26,917,036)	(8,099,627)
Total deficiency in stockholders’ equity	(16,361,742)	(4,521,640)
Total Liabilities and Deficiency in Stockholders’ Equity	2,412,150	2,274,104
Series A Preferred Stock [Member]
CURRENT LIABILITIES
Temporary stock, value		1,564,251
Series C Preferred Stock [Member]
CURRENT LIABILITIES
Temporary stock, value	$ 18,043,557	$ 4,566,502

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	200,000,000	200,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,100,000,000	1,100,000,000
Common stock, shares issued	570,651,636	333,000,327
Common stock, shares outstanding	570,651,636	333,000,327
Series A Preferred Stock [Member]
Temporary equity, shares issued	0	134,109,750
Temporary equity, shares outstanding	0	134,109,750
Series C Preferred Stock [Member]
Temporary equity, shares issued	30,000,000	30,000,000
Temporary equity, shares outstanding	30,000,000	30,000,000
Series B Preferred Stock [Member]
Preferred stock, shares issued	81,000	293,000
Preferred stock, shares outstanding	81,000	293,000

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
REVENUES
COST OF REVENUES
GROSS MARGIN
OPERATING EXPENSES:
General and administrative expenses	4,211,355	4,598,302
Research and development expenses	779,275
Impairment of long-lived assets	16,958	32,136
Depreciation and amortization	6,744	5,301
Total expenses	5,014,332	4,635,739
Loss from operations	(5,014,332)	(4,635,739)
Other expense:
Interest expense	176,672	34,516
Loss on debt extinguishment	149,350
Total other expense	326,022	34,516
Net loss	(5,340,354)	(4,670,255)
Series C deemed dividend	(13,477,055)	(4,440)
Net loss to common shareholders	$ (18,817,409)	$ (4,674,695)
(Loss) income per basic weighted average common share	$ (0.04)	$ (0.01)
Number of weighted average basic and diluted common shares outstanding	500,981,957	326,678,469

Statement of Deficiency in Stoc

Statement of Deficiency in Stockholders' Equity - USD ($)	Common Stock [Member]	Preferred Stock [Member]		Additional Paid-in Capital [Member]		Retained Earnings [Member]	Total
Balance at Dec. 31, 2019	$ 32,280	$ 29		$ 3,304,188		$ (3,424,932)	$ (88,435)
Balance, shares at Dec. 31, 2019	322,800,327	34,402,750
Common shares issued for services	$ 170			36,630			36,800
Common shares issued for services, shares	1,700,000
Common shares issued for intangible assets	$ 850			105,150			106,000
Common shares issued for intangible assets, shares	8,500,000
Warrants issued in connection with debt				54,555			54,555
Warrants issued for services				44,135			44,135
Preferred stock Series A issued for services			[1]		[1]			[1]
Preferred stock Series A issued for services, shares		100,000,000
Preferred stock Series C issued for services			[1]		[1]			[1]
Preferred stock Series C issued for services, shares		30,000,000
Series C deemed dividend					[1]	(4,440)	(4,440)
Net loss						(4,670,255)	(4,670,255)
Balance at Dec. 31, 2020	$ 33,300	$ 29		3,544,658		(8,099,627)	(4,521,640)
Balance, shares at Dec. 31, 2020	333,000,327	164,402,750
Common shares issued for services	$ 872			539,264			540,136
Common shares issued for services, shares	8,715,000
Common shares issued for intangible assets	$ 1,250			1,423,750			1,425,000
Common shares issued for intangible assets, shares	12,500,000
Warrants issued in connection with debt				9,533			9,533
Warrants issued for services				485,487			485,487
Common stock issued for conversion of Preferred stock Series A	$ 13,584		[1]	1,550,667			1,564,251
Common stock issued for conversion of Preferred stock Series A, shares	135,836,702	(134,109,750)
Common stock issued for conversion of Preferred stock Series B	$ 2,826	$ (21)		(2,805)			0
Common stock issued for conversion of Preferred stock Series B, shares	28,266,666	(212,000)
Shares issued for cash	$ 2,752			1,570,248			1,573,000
Shares issued for cash, shares	27,520,442
Shares issued to convert debt	$ 1,094			655,156			656,250
Shares issued to convert debt, shares	10,937,499
Warrant exercises for cash	$ 1,050			523,950			525,000
Warrant exercises for cash, shares	10,500,000
Shares issued to settle payables	$ 37			11,213			11,250
Shares issued to settle payables, shares	375,000
Shares issued to settle debt	$ 200			179,800			180,000
Shares issued to settle debt, shares	2,000,000
Shares issued to settle liability to issue shares	$ 100			7,300			7,400
Shares issued to settle liability to issue shares, shares	1,000,000
Series C deemed dividend					[1]	(13,477,055)	(13,477,055)
Net loss						(5,340,354)	(5,340,354)
Balance at Dec. 31, 2021	$ 57,065	$ 8		$ 10,498,221		$ (26,917,036)	$ (16,361,742)
Balance, shares at Dec. 31, 2021	570,651,636	30,081,000
[1]	Series A and Series C Preferred Stock amounts reflected in mezzanine equity

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (5,340,354)	$ (4,670,255)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,744	5,301
Share based compensation	2,889,567	4,302,978
Amortization of warrant discount	2,545	11,495
Amortization of Original Issue Discount	122,129	19,121
Loss on debt extinguishment	149,350
Impairment of long lived assets	16,958	32,136
Changes in operating assets and liabilities
(Increase) in stock subscription receivable	(25,000)
(Increase) in prepaid expenses	(18,294)
Increase in accounts payable and accrued expenses	592,320	109,131
Net cash used in operating activities	(1,604,035)	(190,093)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(6,834)
Purchase of intangible assets	(14,500)	(34,300)
Net cash used in investing activities	(21,334)	(34,300)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash received for issuance of common stock	1,573,000
Cash received for exercise of warrants	525,000
Cash received for amounts receivable on notes payable	70,000
Cash paid for deferred offering costs	(92,975)
Advances from related party		48,083
Payments on related party advances		(48,083)
Payments on related party notes payable	(50,000)
Cash received from related party notes payable		20,000
Cash received from third party notes payable	110,000	365,000
Net cash provided by financing activities	2,135,025	385,000
Net increase in cash	509,656	160,607
CASH, beginning of year	160,607
CASH, end of year	670,263	160,607
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid in cash	10,000
Income taxes paid in cash
Non-Cash Financing Activities:
Common shares issued for intangible assets	1,425,000	106,000
Common shares issued upon conversion of debt	656,250
Common shares issued upon conversion of preferred stock	1,564,251
Warrants issued as debt discount	9,533	54,555
Series C preferred stock deemed dividend	13,477,055	4,440
Common shares issued to settle liabilities	$ 198,650

NATURE OF OPERATIONS

NATURE OF OPERATIONS	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NOTE 1 - NATURE OF OPERATIONS Curative Biotechnology Inc. (f/k/a Connectyx Technologies Holdings Group, Inc.), (CUBT), is a Florida corporation, formed as a Nevada corporation on June 29, 1995, reincorporated in Florida on October 30, 2007, with a name change November 30, 2020, which conducts business from its headquarters in Boca Raton, Florida. Curative Biotechnology, Inc. is a development stage biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined “Orphan Diseases” with patient populations under 200,000 in the United States. The company leverages management’s experience and business relationships with Life Science research institutions as well as Life Science industry members to acquire Life Science candidates that fit within the company’s business model. The company has established a scientific advisory board with a successful track record of bringing pharmaceuticals to market.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES a) Basis of Presentation b) Use of Estimates (c) Cash and equivalents (d) Prepaid expenses (e) Property and equipment (f) Intangible Assets Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives. Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified. (g) Impairment of Long-Lived Assets Curative Biotechnology, Inc Notes to Financial Statements NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued (h) Financial Instruments and Fair Value Measurements ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments. ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments. FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement. (i) Related Party Transactions (j) Revenue Recognition (k) Stock based compensation Curative Biotechnology, Inc Notes to Financial Statements NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued (l) Income Taxes (m) Net income (loss) per share no . (n) Recent Accounting Pronouncements

LIQUIDITY AND GOING CONCERN CON

LIQUIDITY AND GOING CONCERN CONSIDERATIONS	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY AND GOING CONCERN CONSIDERATIONS	NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company’s financial position and operating results raise substantial doubt about the Company’s ability to continue as a going concern, as reflected by the net loss of approximately $ 5.3 26.9

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 4 - INTANGIBLE ASSETS During the 4 th (a) MABT Covid-19 license 12,500,000 1,425,000 During the 4 th (b) Website 22,500 3 6,250 In March 2020, the Company contracted with a third party to develop and produce a new website for the Company for a contract price of $ 15,000 1,500,000 Curative Biotechnology, Inc Notes to Financial Statements NOTE 4 - INTANGIBLE ASSETS, continued ( c) Patent rights option 1,800 The Company had until September 30, 2021, to advise IEM in writing that it wishes to exercise this Option Right and pay IEM $ 50,000 1,000 (d) IMT504 Patent license 6.5 The total cost for this license is 20 1 7 91,000 2 6.5 3 6.5 (e) National Institute of Health (NIH) Patent license #1 This license calls for the payment of a non-creditable non-refundable license issue royalty of $ 10,000 (f) National Institute of Health (NIH) Patent license #2 This license requires two separate royalty streams of payments: First is a royalty equal to the unreimbursed patent expenses paid by NIH, with an initial amount of $ 8,500 Curative Biotechnology, Inc Notes to Financial Statements NOTE 4 - INTANGIBLE ASSETS, continued (f) National Institute of Health (NIH) Patent license #2 Second is an ongoing royalty schedule: an initial royalty of $ 5,000 The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable, non-creditable royalty of $ 45,000 The patent rights and patent licenses are under development, therefore amortization of the costs has not commenced, as these patent rights and licenses have not been placed in service.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 5 - RELATED PARTY TRANSACTIONS From time to time the Company may enter into non-arms length transactions with related parties, however the Company exercises its best efforts to ensure that such transactions are valued on a basis comparable to a true arms length transaction. During 2020, one officer advanced $ 48,083 During the second quarter of 2021, the remaining two notes from officers of the Company, totaling $ 40,000 10,000

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2021
Notes Payable
NOTES PAYABLE	NOTE 6 - NOTES PAYABLE During the first quarter 2021, 13 of the 15 total notes were converted into 10,937,499 In January 2021, the amounts receivable for notes payable were received. During the first quarter of 2021, the Company entered into two (2) notes payable with a face amount of $ 137,500 25 110,000 six months 25 The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee 1,100,000 9,533 9.24 During 2020, the Company issued thirteen (13) notes payable with a face amount of $ 568,750 , including 25 % OID, for a total amount of cash received of $ 455,000 . The notes are identical and carry a six month maturity. The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee . In connection with the notes, the Company issued warrants to purchase 4,550,000 shares of common stock of the Company, which were recorded as a discount in the amount of $ 54,555 , which is being amortized over the term of the notes. These notes are collateralized by Preferred C shares representing 9.24 % of the issued and outstanding common stock shares. Two officers holding Preferred C shares have pledged the Preferred C shares as this collateral. During the first quarter of 2021, 13 of the 15 note holders converted their notes into shares of common stock at the rate of $ 0.06 per share, for a total of 10,937,499 shares of common stock for a total of $ 656,250 convertible debt. Curative Biotechnology, Inc Notes to Financial Statements

CONVERTIBLE NOTE PAYABLE

CONVERTIBLE NOTE PAYABLE	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
CONVERTIBLE NOTE PAYABLE	NOTE 7 - CONVERTIBLE NOTE PAYABLE In April 2013, the Company entered into a convertible note in the principal amount of $ 97,500 4 90 0.001 128,700 100,000 2,000,000

LIABILITY TO ISSUE COMMON STOCK

LIABILITY TO ISSUE COMMON STOCK	12 Months Ended
	Dec. 31, 2021
Liability To Issue Common Stock
LIABILITY TO ISSUE COMMON STOCK	NOTE 8 - LIABILITY TO ISSUE COMMON STOCK In March 2020, the Company entered into an agreement to issue 1,000,000 7,400

DEFICIENCY IN STOCKHOLDERS EQUI

DEFICIENCY IN STOCKHOLDERS EQUITY	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
DEFICIENCY IN STOCKHOLDERS EQUITY	NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY At December 31, 2021 and 2020, the Company has 1,100,000,000 0.0001 570,651,636 333,000,327 200,000,000 0.0001 The Company accounts for the Series A and Series C preferred stock in accordance with FASB Accounting Standards Codification (ASC) 480, as mezzanine equity due to Series A having a redemption provision and Series C being convertible into a variable number of common shares. SCHEDULE OF STOCKHOLDERS EQUITY No. Shares Par No. Shares Par No. Shares Par No. Shares Par Series A Series B Series C Total No. Shares Par No. Shares Par No. Shares Par No. Shares Par January 1, 2020 34,109,750 $ 3,411 293,000 $ 29 - $ - 34,402,750 $ 3,440 Issuance of shares for services 100,000,000 10,000 - - 30,000,000 3,000 130,000,000 13,000 December 31, 2020 134,109,750 13,411 293,000 29 30,000,000 3,000 164,402,750 16,440 Beginning Balance 134,109,750 13,411 293,000 29 30,000,000 3,000 164,402,750 16,440 Conversion to common shares (134,109,750 ) (13,411 ) (212,000 ) (21 ) - - (134,321,750 ) (13,432 ) December 31, 2021 - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008 Ending Balance - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008 The preferred shares have the following respective rights and privileges: Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date 35 45 5,000,000 Series B Preferred are convertible in common shares of common stock at a conversion price of $ 0.0075 125 Series C Preferred are convertible into common stock aggregating 30 Curative Biotechnology, Inc Notes to Financial Statements NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued During the fourth quarter 2021, the Company issued 13,159,331 25,915,437 523,000 25,000 200,000 21,960 12,500,000 1,425,000 During the third quarter 2021, the Company issued 4,361,111 4,236,111 425,000 250,000 22,500 60,000 60,000 60,000 70,000 300,000 36,720 250,000 28,475 2,000,000 180,000 9,000 1,200,000 During the second quarter 2021, the Company issued 10,000,000 5,000,000 600,000 May 2026 0.11 1,000,000 During the second quarter 2021, the Company issued 250,000 60,000 60,000 60,000 70,000 840,000 210,000 210,000 210,000 210,000 840,000 During the first quarter 2021, the Company issued 125,000 5,575 0.0446 375,000 11,250 135,836,702 203,000 27,066,666 0.06 10,937,499 656,250 10,500,000 10,500,000 6,500,000 6,500,000 325,000 During the 4 th 1,700,000 36,800 0.0216 th 8,500,000 106,000 0.0125 During the 4 th 100,000,000 1,560,840 0.0156 th 30,000,000 4,562,062 0.152 50% of the Series C shares vested upon issuance and the other 50% vest in May 2021. The Company recorded 50% of the compensation expense upon issuance and 50% as a prepaid expense which will be amortized over the remaining of the six month service period. During the 2nd quarter 2020, the Company issued 1,250,000 23,300 0.01864 Curative Biotechnology, Inc Notes to Financial Statements NOTE 9 – DEFICIENCY IN STOCKHOLDERS EQUITY, continued During the 1st quarter 2020, the Company issued 1,500,000 15,000 0.01 A deemed dividend for the Series C preferred stock is calculated and recorded as shares of common stock are issued. This is calculated as the increase in common shares that the Series C would receive upon conversion, as a result of the change in the number of common shares issued and outstanding during the period multiplied by the closing price of the common stock at the end of the period. The deemed dividend was 13,477,055 4,440

WARRANTS

WARRANTS	12 Months Ended
	Dec. 31, 2021
Warrants
WARRANTS	NOTE 10 - WARRANTS During the fourth quarter 2021, the Company issued 403,225 403,225 December 2024 0.11 25,512,212 12,756,106 December 2024 0.09 0.15 During the third quarter 2021, the Company issued 4,236,111 4,361,111 July and August 2026 0.15 0.14 1,000,000 July 2024 0.124 34,382 During the second quarter 2021, the Company issued 5,000,000 10,000,000 May 2026 0.11 5,000,000 0.20 87,249 3,000,000 0.10 155,717 During the second quarter 2021, the Company issued 1,000,000 0.10 51,906 250,000 During the first quarter 2021, the Company issued 10,500,000 525,000 10,500,000 6,500,000 325,000 6,500,000 In the first quarter 2021, the Company issued 1,100,000 the Company in conjunction with the short term debt at the rate of 10 warrants for each $1 loaned. 0.05 9,533 In the first quarter 2021, the Company issued 5,000,000 0.05 40,600 The method utilized to value the warrants was the Black-Scholes model with the following assumption ranges: Expected life - three or five years 0.04 0.10 60.51 31.56 0.05 0.2 0.09 0.83 Curative Biotechnology, Inc Notes to Financial Statements NOTE 10 - WARRANTS, continued During the 4 th 4,550,000 the Company in conjunction with the issuance of short term debt at the rate of 10 warrants for each $1 loaned 0.05 54,555 During the 4 th 6,750,000 0.05 44,135 The method utilized to value the warrants was the Black-Scholes model with the following assumption ranges: Expected life three years 0.03 109.96 30.22 0.05 0.08 0.11

OPTIONS

OPTIONS	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
OPTIONS	NOTE 11 - OPTIONS In the third quarter of 2021, the Company issued options in conjunction with an agreement for Board of Advisor services and the evaluation of certain potential intangible asset acquisitions. These options call for an undivided 1 8,081,037 5 0.11 436,908 50 50% The method utilized to value the options was the Black-Scholes model with the following assumption ranges: Expected life - ten years 0.114 35.13 0.11 1.47

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	12 Months Ended
	Dec. 31, 2021
Investments, All Other Investments [Abstract]
FINANCIAL INSTRUMENTS	NOTE 12 - FINANCIAL INSTRUMENTS (a) Liquidity Risk (b) Interest Rate Risk

GENERAL AND ADMINISTRATIVE EXPE

GENERAL AND ADMINISTRATIVE EXPENSES	12 Months Ended
	Dec. 31, 2021
General And Administrative Expenses
GENERAL AND ADMINISTRATIVE EXPENSES	NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE 2021 2020 Year ended December 31, 2021 2020 Salaries $ 1,016,881 $ 143,065 Share based compensation 2,889,567 4,302,978 Professional fees 225,384 117,860 Other 79,523 34,399 Total general and administrative expenses $ 4,211,355 $ 4,598,302 Curative Biotechnology, Inc Notes to Financial Statements

IMPAIRMENT OF LONG LIVED ASSETS

IMPAIRMENT OF LONG LIVED ASSETS	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
IMPAIRMENT OF LONG LIVED ASSETS	NOTE 14 - IMPAIRMENT OF LONG LIVED ASSETS In the fourth quarter the Company determined that its fixed assets were obsolete and wrote off the undepreciated balance of $ 1,958 In March 2021, when the Company’s new website was placed in service, the remaining unamortized cost of the Company’s old website was written off, for a total of $ 15,000 During the 4 th 34,516

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 15 - INCOME TAXES The Company recognizes deferred tax assets and liabilities for the tax effects of differences between the financial statements and tax basis of assets and liabilities. A valuation allowance is established to reduce the deferred tax assets if it is more likely than not that a deferred tax asset will not be realized. The components of income tax provision (benefit) related to continuing operations are as follows at December 31: SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE 2021 2020 Current $ - $ - Deferred $ - $ - Total tax provisions $ - $ - The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31: SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE 2021 2020 U.S. Federal statutory income tax rate (21 )% (21 )% State income tax, net of federal benefit (4.5 )% (4.5 )% Valuation allowance 25.5 % 25.5 % Total 0.0 % 0.0 % The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2021 2020 Deferred tax assets: Net operating loss carry forwards $ 1,337,957 $ 831,988 Stock based compensation 1,600,548 958,197 Other - (10,061 ) Total 2,938,505 1,780,124 Deferred tax liabilities: - - Less: valuation allowance (2,938,505 ) (1,780,124 ) Net deferred tax assets $ - $ - Curative Biotechnology, Inc Notes to Financial Statements NOTE 15 - INCOME TAXES, continued The change in valuation allowance was ($ 1,158,381 1,021,331 100 The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which temporary differences become deductible. In accordance with the provisions of ASC 740: Income Taxes, we record a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. At December 31, 2021 and 2020, we have no liabilities for uncertain tax positions. We continually evaluate expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 16 - COMMITMENTS AND CONTINGENCIES (a) Other

CONCENTRATIONS OF CREDIT RISK

CONCENTRATIONS OF CREDIT RISK	12 Months Ended
	Dec. 31, 2021
Risks and Uncertainties [Abstract]
CONCENTRATIONS OF CREDIT RISK	NOTE 17 - CONCENTRATIONS OF CREDIT RISK (a) Cash 416,178 no

COVID-19 PANDEMIC AND VARIANTS

COVID-19 PANDEMIC AND VARIANTS	12 Months Ended
	Dec. 31, 2021
Unusual or Infrequent Items, or Both [Abstract]
COVID-19 PANDEMIC AND VARIANTS	NOTE 18 - COVID-19 PANDEMIC AND VARIANTS The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 19 - SUBSEQUENT EVENTS (a) Intangible Assets (b) Senior Secured Note 1,142,857 12.5 The Note carries a 12.5% 874,286 142,857 125,714 Beginning in September 2022, the Company is required to make monthly redemptions at the rate of 110 179,592 125% 1,428,571 The Note is convertible into common stock of the Company upon an event of default, as defined. The lender received five year warrants to purchase 22,857,143 0.0001 1.0 The Note is secured by all the tangible and intangible assets of the Company. NOTE 19 - SUBSEQUENT EVENTS, continued (c) Deficiency in Stockholders Equity 1,000,000 51,750 In January 2022, the $ 25,000 (d) Options 7,465,500 five year 0.05175 155,250

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	a) Basis of Presentation
Use of Estimates	b) Use of Estimates
Cash and equivalents	(c) Cash and equivalents
Prepaid expenses	(d) Prepaid expenses
Property and equipment	(e) Property and equipment
Intangible Assets	(f) Intangible Assets Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives. Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified.
Impairment of Long-Lived Assets	(g) Impairment of Long-Lived Assets
Financial Instruments and Fair Value Measurements	(h) Financial Instruments and Fair Value Measurements ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments. ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments. FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
Related Party Transactions	(i) Related Party Transactions
Revenue Recognition	(j) Revenue Recognition
Stock based compensation	(k) Stock based compensation
Income Taxes	(l) Income Taxes
Net income (loss) per share	(m) Net income (loss) per share no .
Recent Accounting Pronouncements	(n) Recent Accounting Pronouncements

DEFICIENCY IN STOCKHOLDERS EQ_2

DEFICIENCY IN STOCKHOLDERS EQUITY (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
SCHEDULE OF STOCKHOLDERS EQUITY	SCHEDULE OF STOCKHOLDERS EQUITY No. Shares Par No. Shares Par No. Shares Par No. Shares Par Series A Series B Series C Total No. Shares Par No. Shares Par No. Shares Par No. Shares Par January 1, 2020 34,109,750 $ 3,411 293,000 $ 29 - $ - 34,402,750 $ 3,440 Issuance of shares for services 100,000,000 10,000 - - 30,000,000 3,000 130,000,000 13,000 December 31, 2020 134,109,750 13,411 293,000 29 30,000,000 3,000 164,402,750 16,440 Beginning Balance 134,109,750 13,411 293,000 29 30,000,000 3,000 164,402,750 16,440 Conversion to common shares (134,109,750 ) (13,411 ) (212,000 ) (21 ) - - (134,321,750 ) (13,432 ) December 31, 2021 - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008 Ending Balance - $ - 81,000 $ 8 30,000,000 $ 3,000 30,081,000 $ 3,008

GENERAL AND ADMINISTRATIVE EX_2

GENERAL AND ADMINISTRATIVE EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2021
General And Administrative Expenses
SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE	SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE 2021 2020 Year ended December 31, 2021 2020 Salaries $ 1,016,881 $ 143,065 Share based compensation 2,889,567 4,302,978 Professional fees 225,384 117,860 Other 79,523 34,399 Total general and administrative expenses $ 4,211,355 $ 4,598,302 Curative Biotechnology, Inc Notes to Financial Statements

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE	The components of income tax provision (benefit) related to continuing operations are as follows at December 31: SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE 2021 2020 Current $ - $ - Deferred $ - $ - Total tax provisions $ - $ -
SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE	The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31: SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE 2021 2020 U.S. Federal statutory income tax rate (21 )% (21 )% State income tax, net of federal benefit (4.5 )% (4.5 )% Valuation allowance 25.5 % 25.5 % Total 0.0 % 0.0 %
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES 2021 2020 Deferred tax assets: Net operating loss carry forwards $ 1,337,957 $ 831,988 Stock based compensation 1,600,548 958,197 Other - (10,061 ) Total 2,938,505 1,780,124 Deferred tax liabilities: - - Less: valuation allowance (2,938,505 ) (1,780,124 ) Net deferred tax assets $ - $ -

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Dilutive shares of common stock equivalents	0	0

LIQUIDITY AND GOING CONCERN C_2

LIQUIDITY AND GOING CONCERN CONSIDERATIONS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 5,340,354	$ 4,670,255
Accumulated deficit	$ 26,917,036	$ 8,099,627

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	1 Months Ended					3 Months Ended				12 Months Ended
	Sep. 30, 2021	Jan. 31, 2021	Dec. 31, 2020	Oct. 31, 2020	Mar. 31, 2020	Dec. 31, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Common stock issued to acquire license										$ 1,425,000	$ 106,000
Common stock issued for services, value						$ 21,960	$ 325,000	$ 23,300	$ 15,000	540,136	36,800
Common stock issued for services, shares						200,000	6,500,000	1,250,000	1,500,000
Payment for royalty free perpetual license										14,500	$ 34,300
Website [Member]
Finite-Lived Intangible Assets [Line Items]
Common stock issued for services, value			$ 22,500		$ 15,000
Amortization period			3 years
Amortization expense										$ 6,250
Common stock issued for services, shares					1,500,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
License transaction description				The total cost for this license is 20 million shares of the Company’s common stock, issuable in three tranches - 1- 7 million shares upon execution of the license (which have been issued, valued at $91,000), 2- 6.5 million shares upon the submission of an Investigational New Drug (IND) to the FDA and 3- 6.5 million shares upon the successful completion of the first rabies clinical trial of this IND. This license calls for royalties of 50% of the net profit, after reimbursement for development costs, of successfully marketed products utilizing IMT504.
Patents [Member] | Investigational New Drug [Member]
Finite-Lived Intangible Assets [Line Items]
Common stock issued to acquire license, shares				20,000,000
Patents [Member] | Investigational New Drug [Member] | Share-based Payment Arrangement, Tranche One [Member]
Finite-Lived Intangible Assets [Line Items]
Common stock issued to acquire license, shares				91,000
Patents [Member] | Investigational New Drug [Member] | Share-based Payment Arrangement, Tranche One [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Common stock issued to acquire license, shares				1,000,000
Patents [Member] | Investigational New Drug [Member] | Share-based Payment Arrangement, Tranche One [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Common stock issued to acquire license, shares				7,000,000
Patents [Member] | Investigational New Drug [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Common stock issued to acquire license, shares				2,000,000
Patents [Member] | Investigational New Drug [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Common stock issued to acquire license, shares				6,500,000
Patents [Member] | Investigational New Drug [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Common stock issued to acquire license, shares				3,000,000
Patents [Member] | Investigational New Drug [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Common stock issued to acquire license, shares				6,500,000
National Institute of Health Patent License One [Member]
Finite-Lived Intangible Assets [Line Items]
Payment of non-refundable license issue royalty				$ 10,000
National Institute of Health Patent License Two [Member] | Royalty [Member]
Finite-Lived Intangible Assets [Line Items]
Patent expense initial amount payable		$ 8,500
National Institute of Health Patent License Two [Member] | Royalty One [Member]
Finite-Lived Intangible Assets [Line Items]
License extension terms		The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable, non-creditable royalty of $45,000. There are three benchmark royalties - $75,000 upon the initiation of the first Phase 2 Clinical Study; $300,000 upon the completion of Phase 3 Clinical Study and $600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of $100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty
Payment of non-refundable license issue royalty		$ 45,000
Patent expense initial amount payable		$ 5,000
Mid-Atlantic BioTheraputics, Inc [Member]
Finite-Lived Intangible Assets [Line Items]
Common stock issued to acquire license, shares						12,500,000
Common stock issued to acquire license						$ 1,425,000
Mid-Atlantic BioTheraputics, Inc [Member] | Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Proceeds for patent license development				6,500,000
IEM, Inc [Member] | Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Cost of option				$ 1,800
License extension terms	The Company had until September 30, 2021, to advise IEM in writing that it wishes to exercise this Option Right and pay IEM $50,000 in exchange for an exclusive world-wide, royalty free perpetual license. In September 2021, the Company exercised the option to extend the deadline for notification in the contract with IEM, from September 30, 2020 to March 31, 2022, in exchange for the payment of $1,000
Payment for royalty free perpetual license	$ 50,000
Payment for extension	$ 1,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021
Related Party Transaction [Line Items]
Advances from related party		$ 48,083
Officer [Member] | Two Notes [Member]
Related Party Transaction [Line Items]
Payment of principal amount			$ 40,000
Original issue discount			$ 10,000

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2021	Jun. 30, 2021
Short-term Debt [Line Items]
Cash received		$ 70,000
Purchase of common stock warrants		25,915,437		4,236,111	5,000,000
Share Price				$ 0.114
Thirteen Notes [Member]
Short-term Debt [Line Items]
Debt notes converted into shares of common stock	10,937,499
Two Notes Payable [Member]
Short-term Debt [Line Items]
Debt face amount	$ 137,500		$ 568,750
Original issue discount, percentage	25.00%
Cash received	$ 110,000
Maturity term	6 months
Maturity extension description	The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee
Purchase of common stock warrants	1,100,000		4,550,000
Debt discount amount	$ 9,533
Two Notes Payable [Member] | Series C Preferred Stock [Member]
Short-term Debt [Line Items]
Issued and outstanding common stock shares, percentage	9.24%
Thirteen Notes Payable [Member]
Short-term Debt [Line Items]
Debt notes converted into shares of common stock	10,937,499
Original issue discount, percentage			25.00%
Cash received			$ 455,000
Maturity term			6 months
Maturity extension description			The maturity is extendable at the Company’s option for up to three months with a 3% per month extension fee
Debt discount amount			$ 54,555
Share Price	$ 0.06
Debt Conversion, Converted Instrument, Amount	$ 656,250
Thirteen Notes Payable [Member] | Series C Preferred Stock [Member]
Short-term Debt [Line Items]
Issued and outstanding common stock shares, percentage			9.24%

CONVERTIBLE NOTE PAYABLE (Detai

CONVERTIBLE NOTE PAYABLE (Details Narrative) - USD ($)	Apr. 30, 2013	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Issuance of common stock, shares		13,159,331	4,361,111	10,000,000	8,500,000
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Debt instrument face amount	$ 97,500
Debt instrument interest rate	4.00%
Debt conversion price percentage	90.00%
Debt instrument conversion price per share	$ 0.001
Accrued interest							$ 128,700
Debt payment amount						$ 100,000
Issuance of common stock, shares						2,000,000

LIABILITY TO ISSUE COMMON STO_2

LIABILITY TO ISSUE COMMON STOCK (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended				12 Months Ended
	Mar. 31, 2020	Dec. 31, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Issuance of common stock for services, shares		200,000	6,500,000	1,250,000	1,500,000
Issuance of common stock for services, value		$ 21,960	$ 325,000	$ 23,300	$ 15,000	$ 540,136	$ 36,800
Common Stock [Member]
Issuance of common stock for services, shares	1,000,000		125,000			8,715,000	1,700,000
Issuance of common stock for services, value	$ 7,400		$ 5,575			$ 872	$ 170

SCHEDULE OF STOCKHOLDERS EQUITY

SCHEDULE OF STOCKHOLDERS EQUITY (Details) - USD ($)		3 Months Ended					12 Months Ended
		Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			$ (4,521,640)			$ (88,435)	$ (4,521,640)	$ (88,435)
Common shares issued for services		$ 21,960	$ 325,000		$ 23,300	$ 15,000	540,136	36,800
Common shares issued for services, shares		200,000	6,500,000		1,250,000	1,500,000
Conversion to common shares							1,564,251
Balance		$ (16,361,742)		$ (4,521,640)			(16,361,742)	(4,521,640)
Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common shares issued for services				$ 1,560,840
Common shares issued for services, shares				100,000,000
Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			$ 29			$ 29	$ 29	$ 29
Balance, shares			164,402,750			34,402,750	164,402,750	34,402,750
Common shares issued for services
Conversion to common shares	[1]
Conversion to common shares, shares							(134,109,750)
Balance		$ 8		$ 29			$ 8	$ 29
Balance, shares		30,081,000		164,402,750			30,081,000	164,402,750
Preferred Stock [Member] | Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			$ 13,411			$ 3,411	$ 13,411	$ 3,411
Balance, shares			134,109,750			34,109,750	134,109,750	34,109,750
Common shares issued for services								$ 10,000
Common shares issued for services, shares								100,000,000
Conversion to common shares							$ (13,411)
Conversion to common shares, shares							(134,109,750)
Balance				$ 13,411				$ 13,411
Balance, shares				134,109,750				134,109,750
Preferred Stock [Member] | Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			$ 29			$ 29	$ 29	$ 29
Balance, shares			293,000			293,000	293,000	293,000
Common shares issued for services
Common shares issued for services, shares
Conversion to common shares							$ (21)
Conversion to common shares, shares							(212,000)
Balance		$ 8		$ 29			$ 8	$ 29
Balance, shares		81,000		293,000			81,000	293,000
Preferred Stock [Member] | Series C Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			$ 3,000				$ 3,000
Balance, shares			30,000,000				30,000,000
Common shares issued for services								$ 3,000
Common shares issued for services, shares								30,000,000
Conversion to common shares
Conversion to common shares, shares
Balance		$ 3,000		$ 3,000			$ 3,000	$ 3,000
Balance, shares		30,000,000		30,000,000			30,000,000	30,000,000
Preferred Stock [Member] | Series A, B and C Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			$ 16,440			$ 3,440	$ 16,440	$ 3,440
Balance, shares			164,402,750			34,402,750	164,402,750	34,402,750
Common shares issued for services								$ 13,000
Common shares issued for services, shares								130,000,000
Conversion to common shares							$ (13,432)
Conversion to common shares, shares							(134,321,750)
Balance		$ 3,008		$ 16,440			$ 3,008	$ 16,440
Balance, shares		30,081,000		164,402,750			30,081,000	164,402,750
[1]	Series A and Series C Preferred Stock amounts reflected in mezzanine equity

DEFICIENCY IN STOCKHOLDERS EQ_3

DEFICIENCY IN STOCKHOLDERS EQUITY (Details Narrative) - USD ($)	Jan. 20, 2022	Apr. 30, 2013	Aug. 31, 2022	May 31, 2022	Apr. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Aug. 31, 2021	May 31, 2021	Mar. 31, 2020	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Jan. 31, 2022
Class of Stock [Line Items]
Common stock, shares authorized							1,100,000,000					1,100,000,000				1,100,000,000				1,100,000,000	1,100,000,000
Common stock, par value							$ 0.0001					$ 0.0001				$ 0.0001				$ 0.0001	$ 0.0001
Common stock, shares issued							570,651,636					570,651,636				333,000,327				570,651,636	333,000,327
Common stock, shares outstanding							570,651,636					570,651,636				333,000,327				570,651,636	333,000,327
Preferred stock, shares authorized							200,000,000					200,000,000				200,000,000				200,000,000	200,000,000
Preferred stock, par value							$ 0.0001					$ 0.0001				$ 0.0001				$ 0.0001	$ 0.0001
Shares issued												13,159,331	4,361,111	10,000,000		8,500,000
Warrants to purchase of common stock							25,915,437	4,236,111				25,915,437	4,236,111	5,000,000					4,236,111	25,915,437
Common stock value														$ 600,000		$ 106,000				$ 1,573,000
Security deposit							$ 25,000					$ 25,000								25,000
Common shares issued for services, shares												200,000			6,500,000		1,250,000	1,500,000
Common shares issued for services												$ 21,960			$ 325,000		$ 23,300	$ 15,000		$ 540,136	$ 36,800
Shares vested							60,000	250,000	60,000	250,000			60,000	60,000
Warrant maturity date												2024-12	2026-07	2026-05
Warrant exercise price							$ 0.11					$ 0.11		$ 0.11						$ 0.11
Number of common stock to settle the liability to issue shares														1,000,000
Shares issued price per share											$ 0.01				$ 0.06	$ 0.0216	$ 0.01864	$ 0.01			$ 0.0216
Stock Issued During Period, Value, Conversion of Convertible Securities																				$ 1,564,251
Exercise of warrants for services shares															6,500,000
Exchange of shares for services, shares																1,700,000
Exchange of shares for services, valued																$ 36,800				7,400
Vesting rate description																50% of the Series C shares vested upon issuance and the other 50% vest in May 2021. The Company recorded 50% of the compensation expense upon issuance and 50% as a prepaid expense which will be amortized over the remaining of the six month service period.
Deemed dividend																				$ 13,477,055	$ 4,440
Convertible Notes Payable [Member]
Class of Stock [Line Items]
Conversion price percentage		90.00%
Shares issued																				2,000,000
Debt instrument convertible conversion price		$ 0.001
Common shares issued for services, shares													2,000,000
Common shares issued for services													$ 180,000
Forecast [Member]
Class of Stock [Line Items]
Shares vested			70,000		70,000
Subsequent Event [Member]
Class of Stock [Line Items]
Common stock, shares authorized																						1,000,000
Shares vested	250,000			250,000	60,000
Advisory Board [Member]
Class of Stock [Line Items]
Common shares issued for services, shares													250,000	250,000
Common shares issued for services													$ 22,500
Board of Directors [Member]
Class of Stock [Line Items]
Common shares issued for services, shares													300,000
Common shares issued for services													$ 36,720
Advisory Board One [Member]
Class of Stock [Line Items]
Common shares issued for services, shares													250,000
Common shares issued for services													$ 28,475
Employee [Member]
Class of Stock [Line Items]
Common shares issued for services, shares														840,000
Shares vested							210,000												210,000
Employee [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Shares vested						210,000
Employees [Member]
Class of Stock [Line Items]
Shares vested														210,000
Two Employees [Member]
Class of Stock [Line Items]
Common shares issued for services, shares														840,000
MABT's COVID-19 Vaccine [Member]
Class of Stock [Line Items]
Shares issued												12,500,000
Common stock value												$ 1,425,000
Common Stock [Member]
Class of Stock [Line Items]
Shares issued															10,500,000					27,520,442
Warrants to purchase of common stock							403,225	4,236,111				403,225	4,236,111		10,500,000	4,550,000			4,236,111	403,225	4,550,000
Common stock value												$ 523,000	$ 425,000		$ 525,000					$ 2,752
Common shares issued for services, shares											1,000,000				125,000					8,715,000	1,700,000
Common shares issued for services											$ 7,400				$ 5,575					$ 872	$ 170
Warrant exercise price																$ 0.05					$ 0.05
Shares issued price per share															$ 0.0446	$ 0.0125					0.0125
Number of common stock to settle a payable															375,000
Value of common stock to settle a payable															$ 11,250
Shares issued															10,937,499					135,836,702
Stock Issued During Period, Value, Conversion of Convertible Securities															$ 656,250					$ 13,584
Exchange of shares for services, shares																				1,000,000
Exchange of shares for services, valued																				$ 100
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, voting rights																				Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date
Conversion price percentage																				35.00%
Redeemable price percentage																				45.00%
Shares issued																				5,000,000
Common shares issued for services, shares																100,000,000
Common shares issued for services																$ 1,560,840
Perferred stock converted into common stock															135,836,702
Shares issued price per share																$ 0.0156					0.0156
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Redeemable price percentage																				125.00%
Debt instrument convertible conversion price							$ 0.0075					$ 0.0075								$ 0.0075
Number of preferred stock converted								9,000					9,000		203,000				9,000
Perferred stock converted into common stock								1,200,000					1,200,000		27,066,666				1,200,000
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Conversion price percentage																				30.00%
Shares issued price per share																$ 0.152					$ 0.152
Exchange of shares for services, shares																30,000,000
Exchange of shares for services, valued																$ 4,562,062

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)	Jan. 20, 2022	May 31, 2022	Apr. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Aug. 31, 2021	May 31, 2021	Mar. 31, 2020	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Warrants to purchase				25,915,437	4,236,111				25,915,437	4,236,111	5,000,000					25,915,437
Sale of common stock									403,225	4,361,111	10,000,000
Warrant term									2024-12	2026-07	2026-05
Warrant exercise price per share				$ 0.11					$ 0.11		$ 0.11					$ 0.11
Warrants outstanding											$ 87,249
Shares vested				60,000	250,000	60,000	250,000			60,000	60,000
Stock Issued During Period, Value, New Issues											$ 600,000		$ 106,000			$ 1,573,000
Exercise of warrants shares												10,500,000
SharesIssued												6,500,000
Common shares issued for services									$ 21,960			$ 325,000		$ 23,300	$ 15,000	$ 540,136	$ 36,800
Common shares issued for services, shares									200,000			6,500,000		1,250,000	1,500,000
Expected term										10 years		5 years	3 years
Share price					$ 0.114					$ 0.114
Expected volatility rate										35.13%
Exercise price					0.11					$ 0.11
Expected dividend rate										1.47%
Two Peoples [Member]
Warrants to purchase													6,750,000				6,750,000
Warrant outstanding amount													$ 44,135				$ 44,135
Share price													$ 0.03				$ 0.03
Exercise price													$ 0.05				$ 0.05
Subsequent Event [Member]
Shares vested	250,000	250,000	60,000
Legal Services [Member]
Warrants to purchase											3,000,000
Warrant outstanding amount											$ 155,717
Minimum [Member]
Warrant exercise price per share				$ 0.09	0.15				$ 0.09	$ 0.15	$ 0.20					$ 0.09
Minimum [Member] | Two Peoples [Member]
Expected volatility rate													30.22%
Expected dividend rate													0.08%
Maximum [Member]
Warrant exercise price per share				$ 0.15	$ 0.14				$ 0.15	$ 0.14	0.10	$ 0.05				$ 0.15
Maximum [Member] | Two Peoples [Member]
Expected volatility rate													109.96%
Expected dividend rate													0.11%
Maximum [Member] | Legal Services [Member]
Warrant exercise price per share											$ 0.10
Common Stock [Member]
Warrants to purchase				403,225	4,236,111				403,225	4,236,111		10,500,000	4,550,000			403,225	4,550,000
Warrant exercise price per share													$ 0.05				$ 0.05
Warrant outstanding amount													$ 54,555				$ 54,555
Stock Issued During Period, Value, New Issues									$ 523,000	$ 425,000		$ 525,000				$ 2,752
Common shares issued for services								$ 7,400				$ 5,575				$ 872	$ 170
Common shares issued for services, shares								1,000,000				125,000				8,715,000	1,700,000
Warrants, description												the Company in conjunction with the short term debt at the rate of 10 warrants for each $1 loaned.					the Company in conjunction with the issuance of short term debt at the rate of 10 warrants for each $1 loaned
Warrant [Member]
Warrants to purchase				25,512,212	1,000,000				25,512,212	1,000,000	1,000,000	1,100,000				25,512,212
Sale of common stock									12,756,106
Warrant term									2024-12	2024-07
Warrant exercise price per share					$ 0.124					$ 0.124			$ 0.05				$ 0.05
Warrant outstanding amount					$ 34,382					$ 34,382	$ 51,906	$ 9,533
Common shares issued for services												$ 325,000
Warrants [Member]
Warrants to purchase												5,000,000
Warrant exercise price per share												$ 0.05
Warrant outstanding amount												$ 40,600
Warrants [Member] | Minimum [Member]
Share price												$ 0.04
Expected volatility rate												60.51%
Exercise price												$ 0.05
Expected dividend rate												0.09%
Warrants [Member] | Maximum [Member]
Share price												$ 0.10
Expected volatility rate										31.56%
Exercise price												$ 0.2
Expected dividend rate												0.83%

OPTIONS (Details Narrative)

OPTIONS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended					12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Shares issued for cash, shares		13,159,331	4,361,111	10,000,000		8,500,000
Share price			$ 0.114
Shares issued for cash				$ 600,000		$ 106,000	$ 1,573,000
Expected term			10 years		5 years	3 years
Volatility rate			35.13%
Exercise price			$ 0.11
Expected dividend rate			1.47%
Board of Advisory [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
[custom:OptionsPercentage]			1.00%
Shares issued for cash, shares			8,081,037
Proceeds from offering			$ 5
Share price			$ 0.11
Shares issued for cash			$ 436,908
Options vested percentage			50.00%
Board of Advisory [Member] | Subsequent Event [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Options vested percentage	50.00%

SCHEDULE OF GENERAL AND ADMINIS

SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
General And Administrative Expenses
Salaries	$ 1,016,881	$ 143,065
Share based compensation	2,889,567	4,302,978
Professional fees	225,384	117,860
Other	79,523	34,399
Total general and administrative expenses	$ 4,211,355	$ 4,598,302

IMPAIRMENT OF LONG LIVED ASSE_2

IMPAIRMENT OF LONG LIVED ASSETS (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Depreciation	$ 1,958
Indefinite lved intangble assets written off		$ 15,000
Impairment charge			$ 34,516

SCHEDULE OF COMPONENTS OF INCOM

SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Current
Deferred
Total tax provisions

SCHEDULE OF EFFECTIVE RECONCILI

SCHEDULE OF EFFECTIVE RECONCILIATION INCOME TAX RATE (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
U.S. Federal statutory income tax rate	(21.00%)	(21.00%)
State income tax, net of federal benefit	(4.50%)	(4.50%)
Valuation allowance	25.50%	25.50%
Total	0.00%	0.00%

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 1,337,957	$ 831,988
Stock based compensation	1,600,548	958,197
Other		(10,061)
Total	2,938,505	1,780,124
Less: valuation allowance	(2,938,505)	(1,780,124)
Net deferred tax assets

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Deferred tax asset change in valuation allowance	$ 1,158,381	$ 1,021,331
Effective income tax rate percentage	100.00%

CONCENTRATIONS OF CREDIT RISK (

CONCENTRATIONS OF CREDIT RISK (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Risks and Uncertainties [Abstract]
Cash, FDIC insured amount	$ 416,178	$ 0

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Jan. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Purchase of common stock warrants				25,915,437	4,236,111	5,000,000
Exercise price				$ 0.11		$ 0.11
Common stock shares				1,100,000,000			1,100,000,000
Common stock				$ 57,065			$ 33,300
Common Stock, Shares, Issued				570,651,636			333,000,327
Share price					$ 0.114
Subsequent Event [Member]
Subsequent Event [Line Items]
Payment of principal amount	$ 179,592
Common stock shares			1,000,000
Common stock			$ 51,750
Common stock value subscriptions			$ 25,000
Subsequent Event [Member] | Equity Option [Member] | Three Employees [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued			7,465,500
Option term			5 years
Share price			$ 0.05175
Payments to purchase common stock			$ 155,250
Subsequent Event [Member] | Senior Notes [Member]
Subsequent Event [Line Items]
Payment of principal amount		$ 1,142,857
Debt discount percentage		12.50%
Debt instrument, payment terms		The Note carries a 12.5% interest rate with interest only payable monthly from April through August 2022.
Debt instrument, interest rate, percentage		12.50%
Proceeds from debt		$ 874,286
Debt discount	$ 1,000,000	142,857
Legal fees		$ 125,714
Monthly redemptions	110.00%
Mandatory prepayment of original principal amount, percentage	125.00%
Debt instrument, long term debt	$ 1,428,571
Purchase of common stock warrants	22,857,143
Exercise price	$ 0.0001